SCHOTT Pharma AG & Co. KGaA (1SXP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SCHOTT Pharma AG & Co. KGaA (1SXP) has a cash flow conversion efficiency ratio of 0.096x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€75.97 Million ≈ $88.82 Million USD) by net assets (€792.27 Million ≈ $926.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of SCHOTT Pharma AG & Co. KGaA to measure how many days the company can operate on defensive assets alone.
SCHOTT Pharma AG & Co. KGaA - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SCHOTT Pharma AG & Co. KGaA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SCHOTT Pharma AG & Co. KGaA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ebos Group Ltd
AU:EBO
|
0.017x |
|
Signify N.V.
AS:LIGHT
|
0.106x |
|
Coface SA
PA:COFA
|
0.013x |
|
MOBVISTA INC. DL-01
F:6MO
|
N/A |
|
Margun Enerji Uretim Sanayi ve Ticaret AS
IS:MAGEN
|
-0.037x |
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
0.055x |
|
Oyak Cimento Fabrikalari AS
IS:OYAKC
|
0.075x |
|
Valiant Co Ltd
SHE:002643
|
0.049x |
Annual Cash Flow Conversion Efficiency for SCHOTT Pharma AG & Co. KGaA (2020–2024)
The table below shows the annual cash flow conversion efficiency of SCHOTT Pharma AG & Co. KGaA from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see SCHOTT Pharma AG & Co. KGaA market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | €792.27 Million ≈ $926.25 Million |
€225.33 Million ≈ $263.43 Million |
0.284x | +8.37% |
| 2023-06-30 | €692.18 Million ≈ $809.23 Million |
€181.65 Million ≈ $212.37 Million |
0.262x | +2.17% |
| 2022-06-30 | €709.04 Million ≈ $828.95 Million |
€182.12 Million ≈ $212.92 Million |
0.257x | -18.52% |
| 2021-06-30 | €419.42 Million ≈ $490.34 Million |
€132.21 Million ≈ $154.57 Million |
0.315x | -4.69% |
| 2020-06-30 | €315.66 Million ≈ $369.04 Million |
€104.40 Million ≈ $122.05 Million |
0.331x | -- |
About SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a… Read more